---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-037568"
form_type: "8-K"
ticker: "WHWK"
cik: "0001422142"
company_name: "Whitehawk Therapeutics, Inc."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T09:04:25.547865+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "low"
source: SEC EDGAR
---

# Aadi Bioscience reports Q3 2023 results; no financial details in filing

## Summary
- Press release for Q3 2023 results issued on November 8, 2023.
- No revenue, EPS, or other specific figures are included in this filing text.
- Investors need to review the full press release for complete financial data.

## SEC filing metadata
- accession: 0001628280-23-037568
- form_type: 8-K
- ticker: WHWK
- cik: 0001422142
- company_name: Whitehawk Therapeutics, Inc.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: low
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422142/000162828023037568/0001628280-23-037568-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422142/000162828023037568/aadi-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-037568
- JSON: https://secwatch.observer/filing/0001628280-23-037568.json
- Plain text: https://secwatch.observer/filing/0001628280-23-037568.txt

## Key facts
- Earnings Releases
  Whitehawk Therapeutics, Inc. reported financial results for the quarter ended September 30, 2023.
  - Period: the quarter ended September 30, 2023
  - Result: reported results
  source text: On November 8, 2023, Aadi Bioscience, Inc. (the " Company ") issued a press release announcing its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1422142/000162828023037568/0001628280-23-037568-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.